Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Valeant Reports 41% Increase in Second-Quarter Revenue

Valeant Pharmaceuticals International Inc. raised its forecast for full-year earnings after posting a 41 percent increase in second-quarter revenue.

Valeant estimates 2013 adjusted earnings per share of $6 to $6.20, up from a prediction in May of $5.55 to $5.85. Second-quarter revenue excluding one-time items rose to $1.1 billion, the company said today in a statement.

Cash earnings per share increased 54 percent, excluding one-time items, in the second-quarter to $1.34, the company said. Analysts had estimated an EPS of $1.28, according to a survey compiled by Bloomberg.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.